Sonothera Inc. reeled in $60.75 million in a series A financing led by Arch Venture Partners. The funds are earmarked for the continued development of Sonothera’s ultrasound-guided, nonviral, gene therapy platform and treatments. Read More
Switzerland is making moves to allow the import of U.S. FDA-approved medical devices after losing barrier-free access to the EU market and over rising concerns about the dismal pace of implementation of the EU’s upgraded devices regulations. Read More
At the recent Clinic Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, Regenlife SAS presented the design for its Light4life study examining the therapeutic efficacy of the RGn600 device. This trial on more than 100 subjects will evaluate the cognitive impacts of new photobiomodulation technology. Read More
Ironically, one of the casualties of the COVID-19 pandemic is an overdue review and revision of U.S. dual use research of concern (DURC) policies, as well as the Department of Health and Human Services’ Potential Pandemic Pathogen Care and Oversight guidance. Consequently, several senators are asking the White House to halt all ongoing and new viral gain-of-function and DURC studies in the life sciences that involve enhanced pathogens of pandemic potential. Read More
Several studies have indicated that volatile organic compounds (VOCs) in exhaled breath can be altered by lung cancer and serve as identifiable biomarkers. A limitation of using these VOCs as clinical biomarkers has been the fact that hundreds of such molecules are present in exhaled breath and it is experimentally challenging to monitor the molecular concentration changes of all the VOCs and further use them in lung cancer detection. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abiomed, Endra Life Sciences, Medtronic, Merit Medical Systems, Think Surgical, Vicore Pharma Holding. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Apoqlar, Deep Blue Medical. Read More
